Fujifilm Diosynth Biotechnologies expands its biologic manufacturing capabilities at Hillerød site

Published: 6-Nov-2024

The CDMO's first expansion phase introduces six more 20,000 L bioreactors and two downstream processing streams to the facility

CDMO Fujifilm Diosynth Biotechnologies has initiated the first phase of the expansion at its biopharmaceutical site in Hillerød, Denmark.

The expansion will add six mammalian cell bioreactors, which brings the total capacity of the Hillerød site to 12 20,000 L bioreactors, as well as two downstream processing streams. 

According to Fujifilm, fill/finish production will commence by mid 2025, and the expansion will be fully completed and operational by 2026.

This extension will increase the site's footprint to around 51,500m2, while also creating up to 2,200 jobs for local residents.

Fujifilm's expansion of the Hillerød site follows the company's continued investment into its biologics manufacturing capabilities — which includes modular facilities designed to deal with rapid production scaling. 

The site will also only utilise electricity from renewable sources, which contributes to the company's EcoVadis silver certification.

Site Head and Senior VP of Fujifilm Diosynth Biotechnologies, Christian Houborg, commented: “Our operations in Hillerød represent our commitment to being the world-leading partner for life — supporting our customers and their patients globally,” 

“This expansion is a testament to our vision for introducing robust capabilities into the global biopharma landscape, ensuring the timely delivery of critical therapies to those in need.”

CEO and President, Lars Petersen, added: “The Hillerød facility is the first expansion in our global network, which will include further developments in the US, UK, and Japan,”

“By investing in state-of-the-art facilities on both sides of the Atlantic and prioritizing our workforce, we are uniquely positioned to meet the evolving needs of our partners and the patients they serve.”

“This is just the beginning. With our Partners for Life strategy, we are dedicated to fulfilling our promises and ensuring that our global network supports the production of the life-impacting medicines that make patients’ lives better." Lars concluded.

You may also like